

Boris Y Alekseev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4022884/publications.pdf>

Version: 2024-02-01

153
papers

13,499
citations

109321

35
h-index

23533

111
g-index

155
all docs

155
docs citations

155
times ranked

11429
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. <i>European Urology Oncology</i> , 2022, 5, 225-234.	5.4	17
2	Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 274-282.	3.9	11
3	Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2022, 8, 275.	7.1	75
4	Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 1132-1142.	27.0	341
5	Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1616-1622.	1.6	111
6	Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 768-780.	10.7	23
7	The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups. <i>Prostate</i> , 2022, 82, 1237-1247.	2.3	2
8	The role of microRNA in the diagnosis of prostate cancer. <i>Onkourologiya</i> , 2021, 16, 172-180.	0.3	3
9	Diferelin® as an effective chemical castration agent for patients with prostate cancer. <i>Onkourologiya</i> , 2021, 16, 191-196.	0.3	0
10	Large bladder leiomyoma: a case report. <i>Onkourologiya</i> , 2021, 16, 215-219.	0.3	0
11	Surgical treatment of patients with high-risk prostate cancer: long-term outcomes and prognostic factors. <i>Onkourologiya</i> , 2021, 16, 99-111.	0.3	3
12	The R.E.N.A.L. nephrometry score in radiologist's practice. <i>Onkourologiya</i> , 2021, 16, 17-31.	0.3	2
13	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1289-1300.	27.0	956
14	Clinical significance of mutations in DNA repair genes in patients with metastatic prostate cancer. <i>Onkourologiya</i> , 2021, 17, 82-88.	0.3	0
15	An original surgical method for the formation of fascial duplication in the elimination of damage to the anterior rectal wall during prostatectomy. <i>Onkourologiya</i> , 2021, 17, 54-61.	0.3	2
16	Efficacy and safety of lenvatinib and everolimus combination in patients with metastatic renal cell carcinoma progression following targeted antiangiogenic therapy: secondary analysis of data obtained in the Russian multicenter observational study. <i>Onkourologiya</i> , 2021, 17, 31-44.	0.3	1
17	Comparing the efficacy of laparoscopic and open radical prostatectomy: analysis of treatment outcomes in patients with prostate cancer treated in three federal centers. <i>Onkourologiya</i> , 2021, 17, 45-53.	0.3	2
18	<i>FGFR3</i> , <i>TERT</i> , and <i>53</i> mutations and the <i>FGFR3</i> gene expression in bladder cancer as prognostic markers. <i>Onkourologiya</i> , 2021, 17, 89-100.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Impact TMPRSS2-ERG Molecular Subtype on Prostate Cancer Recurrence. <i>Life</i> , 2021, 11, 588.	2.4	7
20	Luteinizing hormone-releasing hormone agonists for prostate cancer patients: routine clinical practice of Russian cancer urologists. <i>Onkourologiya</i> , 2021, 17, 83-92.	0.3	0
21	Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. <i>Circulation</i> , 2021, 144, 1295-1307.	1.6	75
22	Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial. <i>European Journal of Cancer</i> , 2021, 154, 138-146.	2.8	24
23	Long-term treatment outcomes of patients with non-clear cell renal cell carcinoma. <i>Onkourologiya</i> , 2021, 17, 39-46.	0.3	0
24	Experience of using 1 st line combination immunotherapy in patients with metastatic renal cell carcinoma. <i>Onkourologiya</i> , 2021, 17, 47-63.	0.3	1
25	Current capabilities in treatment of non-metastatic castration-resistant prostate cancer: effectiveness, safety, and quality of life of patients taking darolutamide. <i>Onkourologiya</i> , 2021, 17, 78-84.	0.3	0
26	Morphological prerequisites for the formation of fascial duplication in the elimination of damage to the anterior rectal wall during prostatectomy. <i>Innovative Medicine of Kuban</i> , 2021, , 18-25.	0.2	0
27	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 105-120.	10.7	61
28	Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study. <i>European Urology</i> , 2020, 77, 494-500.	1.9	54
29	Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. <i>Nature Medicine</i> , 2020, 26, 1733-1741.	30.7	282
30	Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. <i>New England Journal of Medicine</i> , 2020, 383, 1040-1049.	27.0	225
31	Basic characteristics and features of the molecular genetic test systems designed for non-invasive diagnostics and prognosis of prostate cancer and bladder cancer. <i>Onkourologiya</i> , 2020, 15, 18-29.	0.3	1
32	The validation of threshold decision rules and calculator for APhiG algorithm for clarification of prostate cancer staging before treatment. <i>Onkourologiya</i> , 2020, 16, 43-53.	0.3	1
33	Evaluation of the efficacy and safety of cabazitaxel in combination with prednisone in patients with metastatic castration-resistant prostate cancer who have previously received docetaxel chemotherapy in daily clinical practice. Results of a Russian multicenter prospective study. <i>Onkourologiya</i> , 2020, 16, 66-77.	0.3	1
34	New treatment options for advanced urothelial cancer: a combination of atesolizumab with chemotherapy. <i>Onkourologiya</i> , 2020, 16, 104-117.	0.3	1
35	PI-RADS v2.1: moving towards clarity (comments on the updated version). <i>Onkourologiya</i> , 2020, 16, 15-28.	0.3	1
36	Radium chloride [²²³ Ra] for patients with prostate cancer and skeletal metastases. Clinical recommendations. <i>Onkourologiya</i> , 2020, 16, 114-123.	0.3	0

#	ARTICLE	IF	CITATIONS
37	Comparative clinical and economic analysis of using cabozantinib as second-line therapy for adult patients with advanced renal cell carcinoma. <i>Onkourologiya</i> , 2020, 16, 52-64.	0.3	0
38	Immunosuppressive peculiarities of stromal cells of various kidney tumor types. <i>Onkourologiya</i> , 2020, 16, 29-35.	0.3	4
39	The prevalence of prostate cancer from 2005 to 2010 in terms of patient survival. <i>Onkourologiya</i> , 2020, 16, 126-134.	0.3	0
40	Current opportunities of therapy for patients with non-metastatic castration-resistant prostate cancer. <i>Onkourologiya</i> , 2020, 16, 190-197.	0.3	1
41	Combination of nivolumab and ipilimumab in the treatment of disseminated renal cell carcinoma. Realities and prospects. <i>Onkourologiya</i> , 2020, 16, 38-52.	0.3	0
42	An interim analysis of non-interventional study of the epidemiology and natural history of non-metastatic castration-resistant prostate cancer in Russia. <i>Onkourologiya</i> , 2020, 16, 90-101.	0.3	1
43	ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2974-2986.	1.6	643
44	Differentially Expressed Genes Associated With Prognosis in Locally Advanced Lymph Node-Negative Prostate Cancer. <i>Frontiers in Genetics</i> , 2019, 10, 730.	2.3	21
45	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet, The</i> , 2019, 393, 2404-2415.	13.7	778
46	Novel potential causative genes in carotid paragangliomas. <i>BMC Medical Genetics</i> , 2019, 20, 48.	2.1	4
47	Transcriptome Guided Drug Combination Suppresses Proliferation of Breast Cancer Cells. <i>Bulletin of Experimental Biology and Medicine</i> , 2019, 166, 656-660.	0.8	3
48	Changes in the Metastatic Properties of MDA-MB-231 Cells after IGFBP6 Gene Knockdown Is Associated with Increased Expression of miRNA Genes Controlling INSR, IGF1R, and CCND1 Genes. <i>Bulletin of Experimental Biology and Medicine</i> , 2019, 166, 641-645.	0.8	8
49	Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2019, 20, 686-700.	10.7	496
50	Mutational load in carotid body tumor. <i>BMC Medical Genomics</i> , 2019, 12, 39.	1.5	12
51	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1103-1115.	27.0	1,824
52	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1116-1127.	27.0	2,319
53	Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 1235-1246.	27.0	621
54	Bioinformatic identification of differentially expressed genes associated with prognosis of locally advanced lymph node-positive prostate cancer. <i>Journal of Bioinformatics and Computational Biology</i> , 2019, 17, 1950003.	0.8	16

#	ARTICLE	IF	CITATIONS
55	Autoantibody against arrestin-1 as a potential biomarker of renal cell carcinoma. <i>Biochimie</i> , 2019, 157, 26-37.	2.6	11
56	The role of molecular genetic alterations in sensitivity of the adjuvant intravesical therapy for non-muscle invasive bladder cancer. <i>Onkourologiya</i> , 2019, 14, 124-138.	0.3	2
57	Second line chemotherapy in patients with castration-refractory prostate cancer. From clinical studies to practice. <i>Onkourologiya</i> , 2019, 15, 84-91.	0.3	1
58	Surgical technique stabilization of urethrovesical anastomosis in order to improve the results of early recovery of urine retention after retropubic prostatectomy. <i>Onkourologiya</i> , 2019, 14, 68-78.	0.3	1
59	Overexpression of microRNAs miR-9, -98, and -199 Correlates with the Downregulation of HK2 Expression in Colorectal Cancer. <i>Molecular Biology</i> , 2018, 52, 190-199.	1.3	17
60	HK3 overexpression associated with epithelial-mesenchymal transition in colorectal cancer. <i>BMC Genomics</i> , 2018, 19, 113.	2.8	45
61	Exome analysis of carotid body tumor. <i>BMC Medical Genomics</i> , 2018, 11, 17.	1.5	26
62	Role of IGFBP6 Protein in the Regulation of Epithelial-Mesenchymal Transition Genes. <i>Bulletin of Experimental Biology and Medicine</i> , 2018, 164, 650-654.	0.8	8
63	In Vitro Model for Studying of the Role of IGFBP6 Gene in Breast Cancer Metastasizing. <i>Bulletin of Experimental Biology and Medicine</i> , 2018, 164, 688-692.	0.8	7
64	The effect of ELOVL6 fatty acid elongase inhibition on the expression of genes associated with the metastasis of breast cancer. <i>Russian Chemical Bulletin</i> , 2018, 67, 2307-2315.	1.5	2
65	Expression of Stroma Components in the Lymph Nodes Affected by Prostate Cancer Metastases. <i>Molecular Biology</i> , 2018, 52, 701-706.	1.3	9
66	Features of Construction of the Fluorescent Microscope for the Study of Epithelial-Mesenchymal Transition of Cells in Vitro. <i>Optics and Spectroscopy (English Translation of Optika I Spektroskopiya)</i> , 2018, 125, 137-143.	0.6	0
67	Suppression of NROB2 gene in Clear Cell Renal Cell Carcinoma Is Associated with Hypermethylation of Its Promoter. <i>Molecular Biology</i> , 2018, 52, 414-418.	1.3	5
68	Structural Alterations in Human Fibroblast Growth Factor Receptors in Carcinogenesis. <i>Biochemistry (Moscow)</i> , 2018, 83, 930-943.	1.5	4
69	Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 975-986.	10.7	296
70	New Fluorescent Reporter Systems for Evaluation of the Expression of E- and N-Cadherins. <i>Bulletin of Experimental Biology and Medicine</i> , 2018, 165, 88-93.	0.8	1
71	Transcription Factor SAP30 Is Involved in the Activation of NETO2 Gene Expression in Clear Cell Renal Cell Carcinoma. <i>Molecular Biology</i> , 2018, 52, 385-392.	1.3	8
72	Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5003-5003.	1.6	4

#	ARTICLE	IF	CITATIONS
73	IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2018, 36, 578-578.	1.6	164
74	Individual approach in choosing second-line targeted therapy for metastatic renal cell carcinoma. <i>Onkourologiya</i> , 2018, 14, 68-78.	0.3	2
75	Loop-mediated isothermal amplification: an effective method for express-diagnostics of cancer. <i>Onkourologiya</i> , 2018, 14, 88-99.	0.3	7
76	NEW TREATMENT STANDARD FOR PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. <i>Onkourologiya</i> , 2018, 14, 68-77.	0.3	1
77	Current approaches to selection of the 1st line therapy in patients with metastatic hormone-sensitive prostate cancer. <i>Onkourologiya</i> , 2018, 13, 85-90.	0.3	1
78	Expression of platelet-derived growth factor alpha and beta genes PDGFRA and PDGFRB associated with biochemical recurrence of prostate cancer after radical prostatectomy. <i>Onkourologiya</i> , 2018, 13, 45-50.	0.3	1
79	The problem of early continence recovery after radical prostatectomy. <i>Onkourologiya</i> , 2018, 13, 70-78.	0.3	1
80	Prostate cancer brachytherapy. Experience of the branches of the National Medical Research Center of Radiology. <i>Onkourologiya</i> , 2018, 14, 94-99.	0.3	2
81	Circulating microRNA expression in connection with prostate cancer lymphogenous metastasis. <i>Onkourologiya</i> , 2018, 14, 87-93.	0.3	1
82	Safety of enzalutamide in patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy: a phase II, multicenter, single-arm, open-label study. <i>Onkourologiya</i> , 2018, 14, 117-125.	0.3	0
83	Comparison of the EORTC and CUETO prognostic models in non-muscle-invasive bladder cancer. <i>Onkourologiya</i> , 2018, 14, 162-170.	0.3	0
84	CURRENTLY AVAILABLE TREATMENT OPTIONS FOR METASTATIC RENAL CELL CARCINOMA. <i>Onkourologiya</i> , 2018, 14, 25-36.	0.3	1
85	NEOADJUVANT AND ADJUVANT CHEMOHORMONAL THERAPY IN PATIENTS WITH HIGH-RISK AND VERY HIGH-RISK PROSTATE CANCER: OUR EXPERIENCE. <i>Onkourologiya</i> , 2018, 14, 58-67.	0.3	1
86	Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes. <i>Bulletin of Experimental Biology and Medicine</i> , 2017, 162, 375-378.	0.8	0
87	Changes in the Level of Circulating hsa-miR-297 and hsa-miR-19b-3p miRNA Are Associated with Generalization of Prostate Cancer. <i>Bulletin of Experimental Biology and Medicine</i> , 2017, 162, 379-382.	0.8	23
88	Biomarkers of prostate cancer sensitivity to the Sendai virus. <i>Molecular Biology</i> , 2017, 51, 80-88.	1.3	6
89	Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 352-360.	27.0	1,588
90	Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1532-1542.	10.7	65

#	ARTICLE	IF	CITATIONS
91	Plasma Level of hsa-miR-619-5p microRNA Is Associated with Prostatic Cancer Dissemination beyond the Capsule. <i>Bulletin of Experimental Biology and Medicine</i> , 2017, 163, 475-477.	0.8	8
92	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2017, 390, 2266-2277.	13.7	153
93	MP28-10 PANEL OF 6 MICRORNAS FOR MINIMALLY INVASIVE DIAGNOSIS OF PROSTATE CANCER. <i>Journal of Urology</i> , 2017, 197, .	0.4	3
94	Potentialities of MicroRNA Diagnosis in Patients with Bladder Cancer. <i>Bulletin of Experimental Biology and Medicine</i> , 2017, 164, 106-108.	0.8	2
95	Prediction of the Aggressive Status of Prostate Cancer on the Basis of Preoperative Data. <i>Journal of Communications Technology and Electronics</i> , 2017, 62, 1448-1455.	0.5	1
96	Upregulation of NETO2 gene in colorectal cancer. <i>BMC Genetics</i> , 2017, 18, 117.	2.7	16
97	LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA3-LBA3.	1.6	2
98	Germline nonsense-mutations of the SMARCB1 gene in Russian patients with rhabdoid renal tumors. <i>Onkourologiya</i> , 2017, 13, 14-19.	0.3	2
99	Application of loop-mediated isothermal amplification of DNA for diagnosis of prostate cancer micrometastases in the lymph nodes. <i>Onkourologiya</i> , 2017, 13, 63-66.	0.3	7
100	Molecular markers of paragangliomas/pheochromocytomas. <i>Oncotarget</i> , 2017, 8, 25756-25782.	1.8	36
101	Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer. <i>Current Genomics</i> , 2017, 18, 236-243.	1.6	5
102	Comparative analysis of the PCA3 gene expression in sediments and exosomes isolated from urine. <i>Onkourologiya</i> , 2017, 13, 54-60.	0.3	0
103	Neoadjuvant chemohormonal therapy and radical prostatectomy in a patient with lymphogenic metastatic prostate cancer. <i>Onkourologiya</i> , 2017, 13, 148-154.	0.3	0
104	Vinflunine as second-line therapy for advanced urothelial carcinoma: Russian observational study. <i>Onkourologiya</i> , 2017, 13, 110-118.	0.3	1
105	Multilocular cystic renal neoplasm of low malignant potential: experience of N.N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology. <i>Onkourologiya</i> , 2017, 13, 34-38.	0.3	1
106	Targeted therapy in patients with poor-prognosis renal cell carcinoma. <i>Onkourologiya</i> , 2017, 13, 49-55.	0.3	4
107	Role of tumor-associated macrophages in renal cell carcinoma pathogenesis. <i>Onkourologiya</i> , 2017, 13, 20-26.	0.3	2
108	Important molecular genetic markers of colorectal cancer. <i>Oncotarget</i> , 2016, 7, 53959-53983.	1.8	91

#	ARTICLE	IF	CITATIONS
109	The Dysregulation of Polyamine Metabolism in Colorectal Cancer Is Associated with Overexpression of c-Myc and C/EBP β rather than Enterotoxigenic <i>Bacteroides fragilis</i> Infection. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-11.	4.0	63
110	Mitochondrial dysfunction and oxidative stress in aging and cancer. <i>Oncotarget</i> , 2016, 7, 44879-44905.	1.8	381
111	Effect of lentivirus-mediated shRNA inactivation of HK1, HK2, and HK3 genes in colorectal cancer and melanoma cells. <i>BMC Genetics</i> , 2016, 17, 156.	2.7	33
112	Profile of microRNA in Blood Plasma of Healthy Humans. <i>Bulletin of Experimental Biology and Medicine</i> , 2016, 160, 632-634.	0.8	15
113	MiRImpact, a new bioinformatic method using complete microRNA expression profiles to assess their overall influence on the activity of intracellular molecular pathways. <i>Cell Cycle</i> , 2016, 15, 689-698.	2.6	58
114	Analysis of Plasma microRNA Associated with Hemolysis. <i>Bulletin of Experimental Biology and Medicine</i> , 2016, 160, 748-750.	0.8	32
115	5-Aminolevulinic acid in intraoperative photodynamic therapy of bladder cancer (results of Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 5	2.6	39
116	Differential expression of alternatively spliced transcripts related to energy metabolism in colorectal cancer. <i>BMC Genomics</i> , 2016, 17, 1011.	2.8	50
117	Plasma Levels of hsa-miR-619-5p and hsa-miR-1184 Differ in Prostatic Benign Hyperplasia and Cancer. <i>Bulletin of Experimental Biology and Medicine</i> , 2016, 161, 108-111.	0.8	33
118	MicroRNA hsa-miR-4674 in Hemolysis-Free Blood Plasma Is Associated with Distant Metastases of Prostatic Cancer. <i>Bulletin of Experimental Biology and Medicine</i> , 2016, 161, 112-115.	0.8	30
119	Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4). <i>Annals of Oncology</i> , 2016, 27, 441-448.	1.2	31
120	APHIG: a new multiparameter index for prostate cancer. <i>Onkourologiya</i> , 2016, 12, 94-103.	0.3	4
121	Effects of <i>Abies sibirica</i> terpenes on cancer- and aging-associated pathways in human cells. <i>Oncotarget</i> , 2016, 7, 83744-83754.	1.8	10
122	Resolution on the results of the Meeting of Experts on the treatment of castrate-resistant prostate cancer. <i>Onkourologiya</i> , 2016, 12, 109-110.	0.3	2
123	Surgical treatment of the stricture of the lower third of ureter after radiation therapy of pelvic organs. <i>Onkourologiya</i> , 2016, 12, 68-73.	0.3	4
124	RECORD-4 phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Final OS analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 560-560.	1.6	0
125	Genetic characteristics of the non-clear cell renal cancer. <i>Onkourologiya</i> , 2016, 12, 14-21.	0.3	1
126	Salvage lymphadenectomy in patients with lymphogenic prostate cancer progression after radical treatment: results of a multicenter study. <i>Onkourologiya</i> , 2016, 12, 70-80.	0.3	4

#	ARTICLE	IF	CITATIONS
127	Optimization of sequential targeted therapy. <i>Onkourologiya</i> , 2016, 12, 22-29.	0.3	0
128	RECORD-4 multicenter phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 611-611.	1.6	0
129	The efficacy and safety of vinflunine in second-line therapy of patients with disseminated transitional cell carcinoma of the urinary tract in clinical practice. <i>Onkourologiya</i> , 2016, 12, 74-81.	0.3	1
130	Second-line hormonal therapy with the enzalutamid in patients with castrate-resistant prostate cancer. <i>Onkourologiya</i> , 2016, 12, 87-95.	0.3	1
131	Prospects of 2nd line chemotherapy personalization in patients with metastatic castration-resistant prostate cancer. <i>Onkourologiya</i> , 2016, 12, 104-109.	0.3	0
132	Use of sunitinib in patients with metastatic kidney cancer in real clinical practice. <i>Onkourologiya</i> , 2016, 12, 14-20.	0.3	0
133	A system of a unified approach to interpreting prostate magnetic resonance imaging according to the PI-RADSv2 guidelines. <i>Onkourologiya</i> , 2016, 12, 81-89.	0.3	3
134	Methods for the diagnosis and treatment of oligometastases in patients with prostate cancer and progressive disease after radical treatment. <i>Onkourologiya</i> , 2016, 12, 64-73.	0.3	2
135	Identification of Novel Epigenetic Markers of Prostate Cancer by NotI-Microarray Analysis. <i>Disease Markers</i> , 2015, 2015, 1-13.	1.3	41
136	Own Experience in Treatment of Patients with Penile Cancer Using Photodynamic Therapy. <i>BioMed Research International</i> , 2015, 2015, 1-4.	1.9	7
137	RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon $\hat{I}\pm$ -2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. <i>Annals of Oncology</i> , 2015, 26, 1378-1384.	1.2	64
138	Suppression of ITGB4 Gene Expression in PC-3 Cells with Short Interfering RNA Induces Changes in the Expression of \hat{I}^2 -Integrins Associated with RGD-Receptors. <i>Bulletin of Experimental Biology and Medicine</i> , 2015, 159, 541-545.	0.8	19
139	Molecular genetic mechanisms of drug resistance in prostate cancer. <i>Molecular Biology</i> , 2015, 49, 638-648.	1.3	9
140	Downregulation of OGDHL expression is associated with promoter hypermethylation in colorectal cancer. <i>Molecular Biology</i> , 2015, 49, 608-617.	1.3	37
141	RECORD-4: A multicenter, phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4518-4518.	1.6	5
142	Epigenetic Alterations of Chromosome 3 Revealed by NotI-Microarrays in Clear Cell Renal Cell Carcinoma. <i>BioMed Research International</i> , 2014, 2014, 1-9.	1.9	53
143	MP22-18 IDENTIFICATION OF NOVEL GENE EXPRESSION MARKERS FOR BLADDER CANCER DIAGNOSTICS. <i>Journal of Urology</i> , 2014, 191, .	0.4	1
144	A phase 2 study of $\langle \sup \rangle 99m \langle /sup \rangle$ Tc-trofolastat chloride (MIP-1404) SPECT/CT to identify and localize prostate cancer (PCa) in high-risk patients (pts) undergoing radical prostatectomy (RP) and extended pelvic lymph node (ePLN) dissection compared to histopathology: An interim analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, e16003-e16003.	1.6	1

#	ARTICLE	IF	CITATIONS
145	A phase II study of ^{99m} Tc-trofolostat (MIP-1404) SPECT/CT to identify and localize prostate cancer in high-risk patients undergoing radical prostatectomy (RP) and extended pelvic lymph node dissection (EPLND) compared to histopathology: An interim analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 94-94.	1.6	2
146	Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways. <i>Oncotarget</i> , 2014, 5, 9022-9032.	1.8	43
147	A multinational phase II trial of bevacizumab with low-dose interferon- β 2a as first-line treatment of metastatic renal cell carcinoma: BEVLIN. <i>Annals of Oncology</i> , 2013, 24, 2396-2402.	1.2	25
148	Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3791-3799.	1.6	388
149	Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2013, 31, 760-768.	2.6	297
150	A systematic experimental evaluation of microRNA markers of human bladder cancer. <i>Frontiers in Genetics</i> , 2013, 4, 247.	2.3	18
151	1258 ROLE OF A EXTENDED LYMPH NODE DISSECTION DURING RADICAL NEPHRECTOMY. <i>Journal of Urology</i> , 2011, 185, .	0.4	1
152	Aberrant methylation of p16, HIC1, N33, and GSTP1 in tumor epithelium and tumor-associated cells in prostate cancer. <i>Molecular Biology</i> , 2007, 41, 70-76.	1.3	11
153	323: Diagnostic Efficacy of Sentinel Lymph Nodes Detection during Extended Pelvic Lymphadenectomy in Prostate Cancer Patients. <i>Journal of Urology</i> , 2007, 177, 109-109.	0.4	0